Sponsor Directory

Genentech, Inc. clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 6:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1396

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Stomach Cancer, Gastric (Stomach) Cancer, Neoplasm of Cardioesophageal Junction, Gastrointestinal Stromal Tumor (GIST)
Interventions: bevacizumab, carboplatin, capecitabine; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Advanced Unresectable or Metastatic Solid Malignancy
Interventions: Entrectinib, Inavolisib, Alectinib, Ipatasertib, Atezolizumab, Trastuzumab Emtansine, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, Tucatinib, Investigator's Choice of Chemotherapy, Paclitaxel, Tiragolumab, Pralsetinib; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 38
States / cities: Anchorage, Alaska • Oro Valley, Arizona • Hot Springs, Arkansas + 33 more

Conditions: Sepsis, Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions: TNX-832, Placebo; Biological · Drug
Lead sponsor: Altor BioScience; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 6
States / cities: Miami, Florida • Boston, Massachusetts • St Louis, Missouri + 3 more

Conditions: Healthy Participants
Interventions: Digoxin, Divarasib, Rosuvastatin; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Placebo, Ocrelizumab, Avonex; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2023
U.S. locations: 26
States / cities: Phoenix, Arizona • Berkeley, California • San Francisco, California + 22 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Azithromycin, HP xenon (¹²⁹XE); Drug · Other
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Durham, North Carolina • Charlottesville, Virginia

Conditions: Gastrointestinal Cancer
Interventions: Cobimetinib, Hydroxychloroquine, Atezolizumab; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: New York, New York • Providence, Rhode Island

Conditions: Triple Negative Breast Cancer, Stage IV Breast Cancer, HER2 Negative, Invasive Breast Cancer
Interventions: Atezolizumab, Carboplatin, Laboratory Biomarker, Quality-of-Life Assessment; Drug · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Indianapolis, Indiana • Baltimore, Maryland + 3 more

Conditions: Multiple Sclerosis, Pathologic Processes, Demyelinating Diseases, Nervous System Diseases, Autoimmune Diseases, Immune System Diseases, Primary Progressive Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis
Interventions: Ocrelizumab; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Advanced/Metastatic Tumors
Interventions: Atezolizumab, Tiragolumab, Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Etoposide, Capecitabine, Bevacizumab, Pembrolizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 8
States / cities: Scottsdale, Arizona • Santa Monica, California • New Haven, Connecticut + 5 more

Conditions: Bladder Cancer
Interventions: Cabozantinib, Atezolizumab, Cystectomy; Drug · Procedure
Lead sponsor: Deepak Kilari; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 6
States / cities: St Louis, Missouri • Hackensack, New Jersey • Rochester, New York + 3 more

Conditions: Solid Tumors, Adult
Interventions: VB10.NEO; Biological
Lead sponsor: Nykode Therapeutics ASA; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: San Francisco, California • New Haven, Connecticut • Louisville, Kentucky + 2 more

About this Genentech, Inc. sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where Genentech, Inc. is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Genentech, Inc. trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Genentech, Inc. clinical trials

Filter and sort this sponsor

Live official records

Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome

A Clinical Trial to Investigate the Clinical Drug-Drug Interaction of Divarasib With Probe Substrates of P-Glycoprotein and Breast Cancer Resistance Protein in Healthy Participants

A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

A Study Of ¹²⁹XE MRI To Assess Disease Progression In Patients With COPD Treated With Or Without Azithromycin And Standard-of-Care Medications

Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies

Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer

Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus

Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors

Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer

Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors

About this Genentech, Inc. sponsor directory page